Laboratory Corp. of America (NYSE:LH) had its price target lowered by equities researchers at Barclays from $212.00 to $188.00 in a research report issued to clients and investors on Thursday, BenzingaRatingsTable reports. The firm presently has an “overweight” rating on the medical research company’s stock. Barclays‘s target price indicates a potential upside of 39.97% from the stock’s current price.

Several other research analysts also recently weighed in on LH. ValuEngine upgraded shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Morgan Stanley upped their target price on shares of Laboratory Corp. of America from $199.00 to $211.00 and gave the company an “overweight” rating in a research note on Tuesday, February 18th. Zacks Investment Research upgraded shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating and set a $186.00 target price for the company in a research note on Monday, January 13th. Citigroup upped their target price on shares of Laboratory Corp. of America from $179.00 to $204.00 and gave the company a “neutral” rating in a research note on Friday, February 14th. Finally, Mizuho upped their target price on shares of Laboratory Corp. of America from $174.00 to $190.00 and gave the company a “neutral” rating in a research note on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $196.77.

LH traded up $11.49 during trading on Thursday, hitting $134.31. 77,359 shares of the company’s stock were exchanged, compared to its average volume of 1,514,146. The company has a current ratio of 1.12, a quick ratio of 1.03 and a debt-to-equity ratio of 0.86. Laboratory Corp. of America has a 1 year low of $98.02 and a 1 year high of $196.36. The stock has a 50 day moving average price of $168.58 and a 200 day moving average price of $169.97. The firm has a market cap of $11.46 billion, a P/E ratio of 16.05, a price-to-earnings-growth ratio of 1.47 and a beta of 0.95.

Laboratory Corp. of America (NYSE:LH) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.80 by $0.06. Laboratory Corp. of America had a net margin of 7.13% and a return on equity of 15.37%. The company had revenue of $3 billion during the quarter, compared to the consensus estimate of $2.92 billion. During the same period in the previous year, the firm earned $2.52 earnings per share. Laboratory Corp. of America’s revenue for the quarter was up 7.6% on a year-over-year basis. Analysts forecast that Laboratory Corp. of America will post 11.98 earnings per share for the current fiscal year.

In related news, CAO Peter J. Wilkinson sold 297 shares of the company’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $189.65, for a total value of $56,326.05. Following the sale, the chief accounting officer now directly owns 297 shares of the company’s stock, valued at $56,326.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mark S. Schroeder sold 188 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $188.49, for a total transaction of $35,436.12. Following the completion of the sale, the executive vice president now directly owns 533 shares in the company, valued at $100,465.17. The disclosure for this sale can be found here. Insiders sold 27,413 shares of company stock worth $5,199,483 over the last ninety days. 0.74% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. National Pension Service raised its position in Laboratory Corp. of America by 5.5% during the third quarter. National Pension Service now owns 130,074 shares of the medical research company’s stock valued at $21,852,000 after acquiring an additional 6,761 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in Laboratory Corp. of America by 2.3% during the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 23,022 shares of the medical research company’s stock valued at $3,895,000 after purchasing an additional 507 shares during the last quarter. Bank OZK grew its holdings in Laboratory Corp. of America by 8.6% during the fourth quarter. Bank OZK now owns 3,230 shares of the medical research company’s stock valued at $546,000 after purchasing an additional 255 shares during the last quarter. Public Employees Retirement System of Ohio grew its holdings in Laboratory Corp. of America by 0.4% during the third quarter. Public Employees Retirement System of Ohio now owns 103,630 shares of the medical research company’s stock valued at $17,410,000 after purchasing an additional 408 shares during the last quarter. Finally, Clifford Swan Investment Counsel LLC grew its holdings in Laboratory Corp. of America by 1.5% during the fourth quarter. Clifford Swan Investment Counsel LLC now owns 45,247 shares of the medical research company’s stock valued at $7,654,000 after purchasing an additional 665 shares during the last quarter. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

See Also: How Short Selling Works

Analyst Recommendations for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.